Back to results
US 2022/0009929 A1Published application
Polymorphic forms of ibrutinib
AssigneeCipla Limited
InventorsRamanaiah CHENNURU, Srinivas Laxminarayan PATHI, Geena MALHOTRA, Ramesh DEVARAPALLI
Life of this patent
Estimating the term…
Abstract
Disclosed herein are crystalline polymorphic forms of Ibrutinib, methods for their preparation, pharmaceutical compositions comprising the polymorphic Forms, and their use thereof.
Claims24
A crystalline polymorphic form of Ibrutinib, selected from:
- (a) Form-C2, which is characterized by having an XRPD diffractogram comprising peaks at 6.4, 9.7, 10.4, 16.9, and 18.4±0.2 °2Θ;
- (b) Form-C3, which is characterized by having an XRPD diffractogram comprising peaks at 10.0, 15.3, and 17.3±0.2 °2Θ;
- (c) Form-C5 which is characterized by having an XRPD diffractogram comprising peaks at 12.5, 17 and 22.5±0.2 °2Θ;
- and;
- (d) Form-C6 which is characterized by having an XRPD diffractogram comprising peaks at 4.9, 11.4, and 23.2±0.2 °2Θ.
2 more elements
4-7. (canceled)
14-16. (canceled)
(canceled)
26-28. (canceled)
Dependencies are inferred from the claim text.